Is Drugs Made In America Acquisition Corp. Rights (DMAAR) overvalued? · $1.8M cap
Drugs Made In America Acquisition Corp. Rights (DMAAR) common stock listed on US.
This page asks whether Drugs Made In America Acquisition Corp. Rights (DMAAR) looks expensive on cached numbers — not a short thesis.
No cached income statement for DMAAR, so there is no earnings base to call rich or cheap.
DMAAR currently screens at market cap $1.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DMAAR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DMAAR stock page for the full model, not this heading.
Not investment advice.